Clinical Trial Update: QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a triple regimen of QL1706, lenvatinib, and the AG regimen (nab-paclitaxel plus gemcitabine) as first-line therapy for advan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Lenvatinib (lenvatinib)
• Nab-paclitaxel (paclitaxel protein-bound)
• QL1706

Snippet

Sponsor: Du Juan | Conditions: Advance Pancreatic Cancer | Phase 2 | Status: RECRUITING